Open AccessEfficacy of erlotinib as first-line maintenance therapy in patients with locally advanced or metastatic nonsmall cell lung cancer who have not experienced disease progression or unacceptable toxicity during chemotherapy
Author(s) -
Senthil Rajappa,
Dinesh Chandra Doval,
Jaydip Biswas,
Shekar Patil,
Naresh Somani,
Sankar Sambandam,
Shailesh Arjun Bondarde,
Nitin S Palwe,
Binay Swarup
Publication year - 2017
Publication title -
south asian journal of cancer
Language(s) - English
Resource type - Journals
eISSN - 2278-4306
pISSN - 2278-330X
DOI - 10.4103/2278-330x.202573
Subject(s) - medicine , erlotinib , lung cancer , progression free survival , adverse effect , surgery , chemotherapy , discontinuation , performance status , rash , oncology , cancer , epidermal growth factor receptor
First-line maintenance with erlotinib in nonsmall cell lung cancer (NSCLC) patients without progression after four cycles of chemotherapy was well tolerated and significantly prolonged progression-free survival (PFS) compared with placebo.